Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.1007/s12094-017-1732-0


Título: | Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy |
Fecha de publicación: | 7-ago-2017 |
Editorial: | Springer |
Cita bibliográfica: | Clin Transl Oncol (2018) 20:476–483 |
ISSN: | Print: 1699-048X Electronic: 1699-3055 |
Palabras clave: | Neoadjuvant chemotherapy Breast cancer Lymphocyte-to-monocyte ratio Neutrophil-to-lymphocyte ratio Neutrophil-to-monocyte ratio |
Resumen: | Background: Nowadays, neoadjuvant chemotherapy (nCT) in breast cancer is more and more standardized, not only in advanced tumours but also in those for which there is an attempt to achieve breast-conserving surgery. In literature, we can find evidences of the relationship between several types of tumours and systemic inflammatory response. Our objective is to analyse the prognostic value of blood parameters (lymphocytes, neutrophils, monocytes, lymphocyte-to-monocyte ratio (LMR), neutrophil-to-monocyte ratio (NMR) and neutrophil-to-lymphocyte ratio (NLR) in breast cancer (BC) patients treated with nCT. Methods: A retrospective cohort of 150 breast cancer patients treated with nCT and subsequently with surgery was analysed. Data about the patients, histology, response to chemotherapy and peripheral blood values of lymphocytes, monocytes and neutrophils was collected, and used to calculate the LMR, NMR and NLR. Univariate and multivariate analyses were performed for the variables to see the relationship of the ratios to disease-free survival (DFS) and overall survival (OS). Results: Patients with high LMR (≥5.46) and low NLR (<3.33) were associated with a lower percentage of relapse (P = 0.048 and P = 0.015, respectively) and, above all, NLR was associated with a better survival (P = 0.024), being those factors that predict a good progress. Conclusion: High LMR and low NLR can be considered as favourable prognostic factors in BC patients treated with nCT. |
Autor/es principal/es: | Marín Hernández, C. Piñero Madrona, A. Galindo Fernández, P. J. Ruiz Merino, G. Alonso-Romero, José Luis Parrilla Paricio, P. Gil Vázquez, P. J. |
Versión del editor: | https://link.springer.com/article/10.1007/s12094-017-1732-0 |
URI: | http://hdl.handle.net/10201/146088 |
DOI: | https://doi.org/10.1007/s12094-017-1732-0 |
Tipo de documento: | info:eu-repo/semantics/article |
Número páginas / Extensión: | 8 |
Derechos: | info:eu-repo/semantics/embargoedAccess |
Descripción: | © Federación de Sociedades Espanolas de Oncología (FESEO) 2017. This document is the Published version of a Published Work that appeared in final form in Clinical and Translational Oncology. To access the final edited and published work see https://doi.org/10.1007/s12094-017-1732-0 |
Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
s12094-017-1732-0.pdf | 689,39 kB | Adobe PDF | ![]() Visualizar/Abrir Solicitar una copia |
Los ítems de Digitum están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.